Transplant in the Time of Coronavirus

Transplant in the Time of Coronavirus

On a beautiful Thursday afternoon late last May, my partner and I took the dogs swimming at our secret spot at a nearby reservoir. A sailboat gliding across the water made me reminisce about sailing in the San Francisco Bay while growing up. The first…

Endeavor Raises $62M for New Trials for Taladegib IPF Therapy

Endeavor BioMedicines has raised $62 million in series A funding to support the launch of two Phase 2 trials evaluating taladegib (ENV-101), its investigational candidate for the treatment of idiopathic pulmonary fibrosis (IPF), the company announced in a press release. The therapy is designed to target the underlying…

These Resources Can Help Reduce Anxiety During the Pandemic

Many have noted that the recent holiday season was difficult due to the pandemic, as large family gatherings were discouraged. In some places, Christmas was canceled altogether. Two years ago, I wrote about the difficulty of holiday seasons for patients with idiopathic pulmonary fibrosis (IPF) due to exhaustion, and…

Dosing Begins in 2nd Phase 3 Trial of Antibody Treatment for IPF

Dosing has begun in a second Phase 3 trial testing FibroGen’s investigational antibody pamrevlumab in treating idiopathic pulmonary fibrosis (IPF). Still recruiting eligible patients at sites in three European countries — Georgia, Italy, and Hungary — and in Lebanon, the ZEPHYRUS-2 study (NCT04419558) is expected to enroll 340 people,…

Top 10 Pulmonary Fibrosis Stories of 2020

During 2020, Pulmonary Fibrosis News held to its mission of providing daily coverage of breakthrough discoveries, promising therapies, clinical trials, and other news related to pulmonary fibrosis (PF). As we look forward to continuing to bring news and relevant information to patients, family members, and caregivers dealing with PF…

$2.4M NIH Grant Supports Boston Team Creating Cell Model for IPF

A four-year, $2.4 million federal grant given investigators at Boston University School of Medicine (BUSM) will support work to create a 3D cell model system helping to explain the processes that initiate and drive the progression of idiopathic pulmonary fibrosis (IPF). According to a press release, the project will be…